Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belvarafenib - Hanmi Pharmaceutical

Drug Profile

Belvarafenib - Hanmi Pharmaceutical

Alternative Names: GDC 5573; HM-95573; RG 6185

Latest Information Update: 23 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Amides; Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I Malignant melanoma

Most Recent Events

  • 24 Apr 2024 Genentech terminates its licensing agreement with Hanmi Pharmaceutical for the development and commercialisation of belvarafenib (Roche pipeline, May 2024)
  • 15 Feb 2024 Belvarafenib is still in phase-I trials for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in South Korea (Roche pipeline, February 2024), (NCT03284502)
  • 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top